Monday 11 Aug, 2025 10:09 AM
Site map | Locate Us | Login
   Jupiter Wagons bags orders worth Rs 242 crore from GATX India    Jyoti Structures rises after bagging Rs 639-cr EPC order    Mini Diamonds India gains on securing Rs 18-cr export order from Jewellery Trendz    PG Electroplast Ltd Falls 7.7%    Indian Oil Corporation Ltd Spikes 1.5%    Cupid gains after Q1 PAT climbs 82% YoY to Rs 15 cr    Zydus Lifesciences gets USDFA approval for Prucalopride tablets    Nibe bags $1.2 million defence order from Elbit Systems for Naval Launcher Kits    Cupid Q1 PAT climbs 82% YoY to Rs 15 cr    Bajel Projects Q1 PAT drops 46% YoY to Rs 3 cr    Shilpa Medicare gets Shilpa Medicare approval for novel NAFLD drug NorUDCA    Hindustan Foods posts 17% YoY rise in Q1 PAT; clocks EBITDA of Rs 83.5 crore    Siemens posts PAT of Rs 423 crore in Q3 2025; order backlog rises to Rs 42,845 crore    Yatra Online reports multi-fold PAT to Rs 16 cr in Q1 FY26    Tata Motors Q1 PAT tumbles 63% YoY to Rs 3,924 cr 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Zydus Lifesciences gets USDFA approval for Prucalopride tablets
11-Aug-25   08:23 Hrs IST

The said drug is equivalent to listed drug Motegrity tablets, 1 mg and 2 mg.

Prucalopride is prescribed for chronic idiopathic constipation (CIC), a condition where the cause of constipation is unknown. It helps stimulate peristalsis, natural muscle contractions in the colon, to promote more regular bowel movements. The said tablets will be produced at the company's (SEZ), Ahmedabad.

Prucalopride tablets had annual sales of $186.8 million in the United States (IQVIA MAT June 2025).

As on 31st July 2025, the group has 422 approvals and has so far filed 483 ANDA since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit shed 1% to Rs 1,170.90 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.

The counter fell 1.04% to end at Rs 935.50 on Friday, 8 August 2025.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 43369162
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited